Uremic Toxins in the Intensive Care Units (ICU): Patients With Lactate Acidosis

Verified by: University Hospital, Ghent, July 2011
First Received: September 12, 2008 | Last Updated: July 14, 2011 | Phase: N/A | Start Date: September 2008
Overall Status: Recruiting | Estimated Enrollment: 12
  • …
  • Tell a FriendPrint

Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with lactate acidosis. The sampling of blood and dialysate will be done during dialysis with different durations (4, 6 and 8...

Brief Summary

Official Title: “Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Lactate Acidosis”

Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with lactate acidosis. The sampling of blood and dialysate will be done during dialysis with different durations (4, 6 and 8 h)

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: December 2011

Intervention(s) in this Clinical Trial

  • Procedure: Dialysis during 4 hours
    • Blood and dialysate sampling
  • Procedure: Dialysis during 6 hours
    • Blood and dialysate sampling
  • Procedure: Dialysis during 8 hours
    • Blood and dialysate sampling

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 1
    • Dialysis during 4 hours
  • Experimental: 2
    • Dialysis during 6 hours
  • Experimental: 3
    • Dialysis during 8 hours

Outcome Measures for this Clinical Trial

Primary Measures

  • Toxin removal
    • Time Frame: During dialysis
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Includes ICU patients with lactate acidosis with acute renal failure

Exclusion Criteria:

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: University Hospital, Ghent Other

Overall Clinical Trial Officials and Contacts

Raymond Vanholder, MD, PhD Principal Investigator University Hospital, Ghent  

Overall Contact: Sunny Eloot, PhD  Sunny.eloot@ugent.be

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00752453

Study ID Number: 2008/375

ClinicalTrials.gov Identifier: NCT00752453

Health Authority: Belgium: Institutional Review Board

Website of the University Hospital Ghent

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00752453